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Variability in the eﬀect of subcutaneously administered insulin represents a major challenge in insulin therapy where precise dosing
is required in order to achieve targeted glucose levels. Since this variability is largely inﬂuenced by the absorption of insulin, a deeper
understanding of the factors aﬀecting the absorption of insulin from the subcutaneous tissue is necessary in order to improve
glycaemic control and the long-term prognosis in people with diabetes. These factors can be related to either the insulin
preparation, the injection site/patient, or the injection technique. This review highlights the factors aﬀecting insulin absorption
with special attention on the physiological factors at the injection site. In addition, it also provides a detailed description of the
insulin absorption process and the various modiﬁcations to this process that have been utilized by the diﬀerent insulin
preparations available.
1. Introduction
Insulin has been widely used for blood glucose management
in people with diabetes since its extraction and identiﬁcation
in 1921 by Banting and coworkers. However, despite
signiﬁcant improvements in insulin production, puriﬁcation,
pharmaceutical formulation, and methods of delivery,
microvascular and premature macrovascular complications
remain a leading cause of morbidity and mortality in these
subjects [1–3].
The degree of glycaemic control inﬂuences the progres-
sion of diabetes complications in people with type 1 and
type 2 diabetes [2–6]. The former depend on exogenous
insulin therapy for survival, while many people with type
2 diabetes will eventually—in addition to oral hypoglycaemic
agents—require insulin as a consequence of relative insulin
deﬁciency that worsens with disease progression [7, 8].
Variability in the subcutaneous (SC) absorption and
eﬀect of insulin represents an important source of glucose
variability in patients using insulin and is thus a major
challenge in insulin therapy [9–11]. As the objective of
insulin therapy is to mimic the normal physiological release
of insulin in order to establish normoglycaemia, variability
in the eﬀect of insulin will give rise to an unpredictable
therapeutic response resulting in inadequate glycaemic
control and increased risk of hypoglycaemia. One important
consequence of this lack of predictability is undertreatment
of the disease, as many people with diabetes fear the hypogly-
caemic events that are associated with overtreatment.
Although there is no formal deﬁnition of the term
“glucose variability,” it is commonly understood as how
blood glucose levels deviate from a mean or ideal value over
time (hours and days)—a phenomenon that can also be
described as “glucose ﬂuctuation” [12]. Glucose variability
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is also observed as day-to-day diﬀerences in glucose values
obtained at set time points, or in the 24 h blood glucose
proﬁle, and such variability goes under the term “reproduc-
ibility” or “predictability” [12].
In people using SC insulin therapy, the term “within-
subject variability” usually describes diﬀerences in the blood
glucose response from one injection to another in the
same individual [12]. This variability contributes to glucose
variability and is the sum of two components: (1) a pharma-
cokinetic component, determined by the extent and rate of
absorption, distribution, and clearance of insulin and (2) a
pharmacodynamic component, determined by insulin’s
metabolic eﬀects [10]. Since the variability in insulin
pharmacokinetics—which is commonly understood as vari-
ability in exposure between injections or within-subject
variability—for most insulin preparations is largely deter-
mined by the absorption proﬁle of insulin, an understanding
of the factors inﬂuencing insulin absorption is necessary in
terms of improving glycaemic control and the long-term
prognosis in people with diabetes.
2. Insulin Absorption
2.1. Structure and Composition of Subcutaneous Tissue. The
most commonly used administration route for insulin is the
SC route [13].
The SC tissue, located between the skin (epidermis and
dermis) and muscle, consists of adipose tissue separated into
fat lobules by a network of connective tissue septae that are
mainly composed of collagen (primarily type I, III, and V),
elastin, and glycosaminoglycans (GAGs) and contain both
blood and lymph vessels (Figure 1) [14–16].
Connective tissue represents the majority of the
extracellular matrix (ECM). It constitutes around 10% of
the SC compartment and is a physiological barrier to insulin
delivery after SC administration since insulin has to travel
through the connective tissue—following the path of least
resistance—before entering systemic circulation [17–19].
Moreover, insulin has been reported to bind to proteins pres-
ent in the extracellular matrix such as collagen that may thus
act as tissue reservoirs [16]. In addition—for acylated insulin
analogues—albumin binding in the SC tissue is an important
mechanism in delaying absorption from the SC tissue [20].
Fibroblasts, located in the connective tissue, synthesize
the components of ECM, including collagen, elastin, proteo-
glycans, and GAGs. The structure of SC tissue is determined
mainly by collagen, while elastin provides elasticity. The
negatively charged GAGs and proteoglycans attract water
molecules to form the gel-like phase of the ECM and control
interstitial ﬂuid content [17]. Under normal circumstances,
ﬁbroblasts, adipocytes, and macrophages are the primary cell
types residing in the connective tissue [21].
Fat lobules contain few arterioles and venules com-
pared to the connective tissue, and they are devoid of
lymphatics [17, 22, 23]. Instead, lymph capillaries are
located in a plexus between dermis and subcutis where
they drain into lymph vessels located in the interlobular
connective tissue septae [17]. Compared to blood capillaries,
endothelial cells of lymphatic capillaries lack tight junctions,
allowing uptake of larger molecules [17, 24].
The interstitial ﬂuid in the ECM derives from leakage of
plasma through the blood capillaries due to pressure diﬀer-
ences between arterioles and venules—what is not recovered
by the venules is absorbed by the lymphatic system [21].
Hence, the composition of the interstitial ﬂuid is somewhat
similar to that of plasma in terms of ionic composition and
pH [21]. However, it does have a considerable lower content
of protein (e.g., albumin and globulin), protein-bound ions
(i.e., calcium and magnesium), and free cations [25–27].
Although the dermal route may actually oﬀer a more
rapid absorption of insulin compared to the SC route, dermal
injections have traditionally been more diﬃcult to perform
and may result in increased immune response activation,
injection pain, and insulin leakage [28]. Microneedles may
overcome some of these issues, although patients may
experience more pain due to a high delivery pressure as a
result of increased tissue density and decreased needle
diameter [29–31], making this route less suitable for injection
of larger volumes.
2.2. Absorption of Insulin from Subcutaneous Tissue. Soluble
human insulin consists of diﬀerent oligomers in a chemical
equilibrium. These include insulin monomers, dimers, and
hexamers with a molecular weight of 6 kDa, 12 kDa, and
36 kDa, respectively [32]. Furthermore, certain insulin
analogues also depend on the formation of dihexamers and
multihexamers as a mechanism of protraction in the SC
tissue [20, 33], as will be elaborated in the section on insulin
types. The concentration of each insulin oligomer is deter-
mined by the equilibrium constants KDH and KMD between
the insulin hexamers and dimers, and dimers and monomers,
respectively [34] (Figure 2).
Upon injection into the SC tissue, insulin monomers and
dimers are readily absorbed by blood capillaries [32]. Insulin
hexamers, however, are not absorbed into the capillaries but
can to some extent be absorbed by the lymphatic system due
Epidermis
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Muscle
Figure 1: An overview of the layers of the skin and muscle. Upon
injection into the subcutaneous compartment, insulin can either
be absorbed by blood capillaries (red) and/or lymphatic capillaries
(green). Adapted with permission from Taylor & Francis and Frost
GI: Recombinant human hyaluronidase (rHuPH20): An enabling
platform for subcutaneous drug and ﬂuid administration. Expert
Opin Drug Deliv (2007) 4(4):427–440. © 2007 Taylor & Francis.
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to their larger size [32, 34]. For storage purposes, excipients
are usually added to the insulin formulation, and this shifts
the equilibrium of insulin oligomers towards the hexamers
by increasing KDH [32, 34]. These excipients include zinc,
which is needed to form insulin hexamers, and phenol
and/or phenol-like substances that stabilize the hexamers
and act as preservatives [32]. When injected into the SC
tissue, lipophilic excipients such as phenol and meta-cresol
as well as zinc disperse away from the insulin depot into
the adipose tissue, which reduces KDM allowing for the
subsequent dissociation of insulin hexamers into dimers
and monomers before transcapillary transport [35]. Absorp-
tion of insulin analogues generally follows a pattern similar to
that of human insulin. However, due to modiﬁcations to the
insulin molecule, these analogues are associated with
diﬀerent pharmacokinetic proﬁles, as will be outlined in the
next section.
In order to assess pharmacokinetic variability, the factors
inﬂuencing insulin absorption need to be considered. These
factors are primarily related to the insulin preparation
(physical-chemical factors), the injection site/patient (physi-
ological/endogenous factors), or the injection technique.
3. Physical-Chemical Factors that Influence
Insulin Absorption
3.1. Insulin Type. Since the introduction of recombinant
DNA technology in the 1980s, the insulin preparations used
today contain recombinant human insulin and/or analogues
of human insulin as the active ingredient [7]. Based on time
of onset and peak and duration of pharmacologic eﬀect,
insulin preparations can be divided into rapid-, short-, inter-
mediate-, and long-acting insulin preparations [7, 36–40]
(Table 1). The rapid- and short-acting insulin preparations
are also known as prandial insulin, because they are taken
at mealtime in order to cover insulin needs for glucose
utilization. The intermediate- and long-acting insulin
preparations are often referred to as basal insulin. They are
typically only administered once or twice daily and serve to
control glucose production. A basal and prandial/postpran-
dial release of insulin to the blood stream—either from the
pancreas or by means of exogenous administration—is
essential in order to achieve normoglycaemia 24 hours/day.
Insulin therapy should thus ideally mimic the physiological
release rate of insulin as closely as possible. Moreover, some
insulin products are available as mixtures in biphasic
premixed or soluble formulations that provide both prandial
and basal coverage [7, 41] (Table 1).
In order to elicit a metabolic eﬀect in insulin-sensitive
tissues after SC administration, insulin needs to travel
through the ECM and enter the systemic circulation. As
previously mentioned, the route of absorption depends on
the insulin oligomer of interest: insulin monomers and
dimers are readily absorbed by blood capillaries, whereas
insulin hexamers are absorbed into the lymph [32, 34]. Fur-
thermore, the oligomeric equilibrium also determines the
rate of insulin absorption, since an inverse relationship exists
between the association state/overall size of insulin and the
fractional disappearance rate from the injection site [64].
Hence, the rate of insulin absorption is fastest for monomers
followed by dimers and hexamers, respectively [35, 64]. This
has been exploited in the genetic engineering of insulin
analogues used in rapid-acting insulin preparations (insulin
aspart, insulin lispro, and insulin glulisine), which have sub-
stitutions or minor alterations in the amino acid sequence
relative to human insulin [65]. In the SC tissue—in the
absence of zinc and phenol—these modiﬁcations give rise
to a reduced self-association of insulin monomers into
dimers compared to human insulin due to a lower KMD
and thus yield a larger fraction of insulin monomers in the
SC tissue [32]. The result is a more rapid absorption from
the SC tissue with faster onset of action, a higher maximum
plasma concentration (Cmax), and shorter duration of action
compared to human insulin [7, 66, 67]. Not only does the
rapid absorption proﬁle associated with rapid-acting insulin
preparations allow for a more eﬀective correction of inciden-
tal hyperglycaemia but also the preparations can be injected
at a shorter time prior to meal intake, increasing the ﬂexibil-
ity of their use [68]. Foremost, the shorter duration of action
associated with these preparations reduces the need for a
snack between meals in order to counteract intermeal
hyperinsulinemia [69, 70]. Novel approaches in achieving
even faster absorption of insulin upon SC administration
include the addition of excipients such as niacinamide
and L-arginine to the insulin aspart formulation [71] and
citrate and treprostinil [72–75] or BioChaperone to the
insulin lispro formulation [76] and coformulation of insulin
with hyaluronidase [77, 78].
Monomer Dimer Hexamer
KMD KDH
Figure 2: Relationship between the insulin oligomers (monomers, dimers, and hexamers) and the equilibrium constants KDH and KMD.
Adapted and printed with permission from Elsevier and Rasmussen: Insulin aspart pharmacokinetics: an assessment of its variability and
underlying mechanisms. Eur J Pharm Sci (2014) 62: 65–75. © 2014 Elsevier.
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In contrast to rapid-acting insulin preparations, interme-
diate- and long-acting insulin preparations exhibit a delayed
absorption proﬁle compared to human insulin. Insulin
suspensions were the only basal insulin formulations
available before the introduction of insulin analogues. The
neutral protamine Hagedorn (NPH) insulin preparation
contains human insulin as the active ingredient. It is associ-
ated with intermediate onset of action due to the addition
of the basic protein protamine to the insulin formulation that
prolongs its pharmacokinetic proﬁle [34, 79]. The crystals in
the NPH suspension are formed by mixing human insulin,
protamine, zinc, and phenolic substances. Whereas soluble
insulin diﬀuses in the SC tissue, insulin crystals will remain
near the injection site. Before dissociation of hexamers into
dimers and monomers, these crystalline structures need to
dissolve, and this process not only prolongs the absorption
phase of NPH insulin but also contributes to pharmacoki-
netic variability between injections [10, 18, 80, 81]. In
contrast to newer insulin products that are available in
homogenous solutions, NPH insulin is a suspension and
requires shaking before use. Consequently, inadequate resus-
pension represents a signiﬁcant source of pharmacokinetic
variability associated with NPH insulin [82]. Furthermore,
the shape and size of the crystals vary between injections,
and these crystals appear to be quite sensitive to changes in
subcutaneous blood ﬂow (SBF) [18]. Finally, compared to
insulin analogues used in intermediate- or long-acting
insulin preparations, NPH insulin is associated with peaks
in exposure, which increases the risk of nocturnal hypogly-
caemia when administered in the evening [83]. The result is
an insulin with a pharmacokinetic proﬁle that poorly mimics
the peak-less basal release of insulin [81]. NPH insulin is also
available in a biphasic mixture with short- or rapid-acting
insulin preparations [7] (Table 1).
Compared to native human insulin, the insulin glargine
analogue contains one modiﬁcation in the amino acid
sequence at position 21A, where asparagine has been replaced
by glycine, and two arginines at the end of the B chain that
are remnants from the conversion of proinsulin to insulin
[84, 85]. Whereas human insulin has an isoelectric point of
pH5.4, insulin glargine has an isoelectric point of pH7,
which renders the insulin molecule soluble in acidic solution
(pH4) [84]. Upon SC injection, the acidic solution is
neutralised leading to formation of microprecipitates from
which small amounts of insulin glargine are continuously
released to the circulation [55]. The acid pH of the insulin
glargine formulation makes it challenging to mix with neu-
tral formulations of other insulin preparation [55, 84, 86].
A diﬀerent approach in reducing the rate of insulin
absorption has been to attach a polyethylene glycol (PEG)
polymer chain to the insulin molecule (PEGylation). This
has been done in development of the PEGylated version of
the analogue insulin lispro which has been reported to be
associated with a half-life of 2–3 days in people with type 2
diabetes [87]. In comparison, the analogue insulin degludec,
which will be introduced below, has a half-life of approxi-
mately 25 hours [88]. PEGylation not only slows insulin
absorption from the SC tissue but also reduces the insulin
clearance rate [89–91]. Since PEGylation increases the
hydrodynamic size of the insulin molecule, most of the
Table 1: An overview of the insulin categories, types, and available concentrations.
Category Type Insulin molecule Product name Units/millilitre and manufacturer
Prandial
Rapid-acting
Insulin aspart
Fiasp®
NovoLog®/NovoRapid®
100U (Novo Nordisk) [39]
100U (Novo Nordisk) [42, 43]
Insulin lispro Humalog® 100U, 200U (Eli Lilly) [44, 45]
Insulin glulisine Apidra® 100U (Sanoﬁ-Aventis) [46]
Short-acting Human insulin
Novolin® R/Actrapid®
Humulin® R U-100
Humulin R U-500
40U, 100U (Novo Nordisk) [47, 48]
100U (Eli Lilly) [49]
500U (Eli Lilly) [50]
Basal
Intermediate-acting
NPH insulin
Novolin N/Insulatard®
Humulin N
40U, 100U (Novo Nordisk) [51, 52]
100U (Eli Lilly) [53]
Insulin detemir Levemir® 100U (Novo Nordisk) [54]
Long-acting
Insulin glargine
Lantus®
Toujeo®
100U, (Sanoﬁ-Aventis) [55]
300U (Sanoﬁ-Aventis) [37]
Insulin degludec Tresiba® 100U, 200U (Novo Nordisk) [40]
Insulin mixtures/
combinations
Intermediate-acting
and rapid/short-acting
NPH/human insulin
Novolin 70/30/
Mixtard® 30/40/50
Humulin 70/30
Ratio 70/30, 60/40, and 50/50
40U, 100U (Novo Nordisk) [56, 57]
ratio 70/30100U (Eli Lilly) [58]
Insulin aspart
protamine/aspart
NovoLog® Mix 70/30+ 50/50/
NovoMix® 30/50/70
Ratio 70/30, 50/50, and 30/70
100U (Novo Nordisk) [59–61]
Insulin lispro
protamine/lispro
Humalog Mix 75/25+ 50/50
Ratio 75/25 and 50/50
100U (Eli Lilly) [62, 63]
Long-acting and
rapid-acting
Insulin
degludec/insulin
aspart
Ryzodeg®
Ratio 70/30
100U (Novo Nordisk) [41]
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insulin likely enters the circulation through the lymphatic
route [90, 92]. However, rather than slow lymphatic
transport, the delayed SC absorption may be a result of slow
interstitial transport of PEGylated insulin molecules [90].
While PEGylated insulins may provide improved glycaemic
control and reduce the risk of hypoglycaemia compared to
use of other analogues, concerns have been raised regarding
liver fat accumulation and elevations in both triglycerides
and liver enzymes which lead to termination of the
PEGlispro clinical development programme [89, 93].
Another strategy to prolong the insulin absorption is by
acylation of the insulin molecule—a modiﬁcation imple-
mented in the design of the analogues insulin detemir and
insulin degludec. With insulin detemir, this results in an
increased dihexamer formation and subsequent albumin
binding at the injection site which leads to a delayed absorp-
tion from the SC tissue [20]. After entering the circulation as
monomers, insulin detemir is bound to albumin, which
further delays its distribution to peripheral tissues and
reduces the insulin clearance rate [20]. Insulin degludec, on
the other hand, exists in a dihexameric state in the insulin
formulation in the presence of zinc and phenol. Upon SC
injection, phenol diﬀuses away, which gives insulin degludec
the ability to self-associate into multihexamers [33, 94]
from which there is a slow, sustained release of insulin
monomers [33]. The result is a 24h coverage associated with
daily injections of the insulin degludec preparation [33, 40].
The slow release of monomers from the multihexameric
complexes is hypothesized to be the rate-limiting step in
absorption of insulin degludec [33]. Like insulin detemir,
insulin degludec binds to circulating albumin upon absorp-
tion [40, 89]. In general, albumin binding in the circulation,
together with insulin solubility before and after SC injection,
is considered to contribute to the observed reduction in
the pharmacokinetic and pharmacodynamic variability of
insulin detemir and insulin degludec [20, 33, 80, 95–97].
3.2. Concentration and Volume. In addition to the insulin
type and excipients added to the formulation [32, 34], the
association state of soluble insulin is also concentration-
dependent; dilution shifts the oligomeric equilibrium from
hexamers towards dimers and monomers [32, 34]. Hence,
the fraction of oligomers is a function of the total insulin
concentration in the formulation and in the SC compartment
[32] (Figure 3). Consequently, it is not surprising that an
inverse relationship exists between insulin concentration
and absorption rate from the injection depot [64, 98, 99].
Diﬀusion of insulin from the injection depot into the
capillaries continuously increases the absorption rate, since
a reduced concentration favours a larger fraction of mono-
mers and dimers in the remaining depot [35]. Conversely,
an increased depot concentration delays absorption and
reduces the maximum plasma concentration, Cmax [18]. This
applies for the human insulin 500U formulation that is
associated with a reduced Cmax and prolonged exposure, thus
providing both prandial and basal coverage [100, 101].
The insulin concentration also aﬀects the pharmaco-
kinetics of insulin suspensions. For NPH insulin, the
concentration of insulin crystals increases with insulin
concentration with delayed SC absorption as a result
[34]. Finally, the pharmacokinetics of soluble insulin that
precipitates in the SC tissue is also aﬀected by insulin
concentration. The new insulin glargine 300U formulation
is associated with a prolonged pharmacokinetic and phar-
macodynamic proﬁle compared to the 100U formulation
[37, 102]. The mechanism of protraction is attributable
to the reduction of the injection volume by two-thirds that
results in a smaller precipitate surface area from which
absorption can occur [37].
The eﬀect of concentration does however not apply to all
insulin preparations. The 200U insulin degludec and insulin
lispro formulations have both been reported to meet the
bioequivalence criteria when compared to the 100U formu-
lations [103, 104]. For insulin degludec, it has been proposed
that because the release of insulin monomers occurs at the
end of each multihexameric chain, this makes the injection
depot less susceptible to changes in the diﬀusion area
associated with changes in injection volume [33, 101].
For insulin lispro, it appears that the increased zinc added
to the formulation ensures bioequivalence [101, 104].
Besides a prolonged pharmacokinetic proﬁle associated
with use of some concentrated insulin preparations, their
use also reduces the injection volume necessary, which in
particular favours their use in highly insulin-resistant
patients requiring high doses of insulin [100, 105, 106].
The eﬀect of depot expansion can explain why higher
injection volumes generally give rise to relatively slower
insulin absorption [34, 98, 107]. Following SC injection, an
injection depot is formed in the SC tissue that—for soluble
insulin that does not precipitate in the SC tissue—diﬀuses
and increases in volume, resulting in a concurrent dilution
of insulin. The relative increase in depot volume is much
faster for small compared to larger volume depots. Conse-
quently, dilution of the depot occurs faster for small volume
depots, giving rise to a relatively faster absorption [34]. In
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Figure 3: Relative abundance (%) of insulin hexamers, dimers, and
monomers as a function of total concentration Cτ. Printed with
permission from Elsevier and Søeborg: Absorption kinetics of
insulin after subcutaneous administration. Eur J Pharm Sci (2009)
36: 78–90. © 2009 Elsevier.
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addition, a smaller depot volume will have a relatively
larger surface-to-volume ratio which increases the diﬀusion
area of the injection depot [101]. In this way, the availability
of insulin pumps—which oﬀers the advantage of injection of
small volumes—or use of a dispersed injection strategy can
facilitate an even more rapid absorption from the SC
tissue [108, 109].
In addition to delaying insulin absorption by decreasing
the surface-to-volume ratio, larger injection volumes may
also exert a depressive eﬀect on the microcirculation due to
an increase in interstitial ﬂuid pressure, thus further delaying
absorption [110].
Exogenous factors inﬂuencing insulin absorption are
summarized in Table 2.
4. Physiological Factors and Factors Related to
the Injection Technique That Influence
Insulin Absorption
4.1. Subcutaneous Blood Flow. One major contributor to the
rate of insulin absorption is SBF at the injection site [9, 10].
Increased SBF results in recruitment of blood capillaries,
which in turn increases the capillary exchange surface in
the SC compartment. Consequently, the insulin absorption
is accelerated [113, 114].
SBF is inﬂuenced by numerous factors in a complex
interplay between, for example, site of injection, temperature,
exercise, obesity, body position, blood pressure, use of
vasodilating/vasoconstricting drugs, and smoking, many of
which have been reported to inﬂuence the pharmacokinetic
proﬁle of insulin [10, 111, 113–129] (Table 3). Some of the
factors will be discussed in more detail below.
4.2. Injection Site. The pharmacokinetic proﬁle of insulin is
aﬀected by the injection site. Hence, the injection region
and administration route (e.g., SC versus intramuscular)
inﬂuence the absorption proﬁle of insulin [98, 111, 115,
118, 122–125, 130]. This eﬀect is probably to a large extent
determined by diﬀerences in SBF between the injection sites,
but diﬀerences in insulin degradation might also be a factor
of importance [9, 114]. Commonly used regions for SC
injection include the upper arm/deltoid, abdomen, outer
thighs, and buttocks [13]. As insulin is absorbed fastest from
the abdomen, slower from the arm followed by thighs and
buttocks, choice of injection region may for many insulin
preparations inﬂuence the metabolic response to insulin
[67, 111, 115, 118, 122–125, 130, 131]. Let us look at a few
examples on how diﬀerent injection regions inﬂuence the
pharmacokinetic proﬁle of insulin. Injection of human
insulin and insulin lispro into the abdominal region has been
reported to result in greater and earlier Cmax compared to the
Table 2: Factors related to the insulin preparation and their eﬀect on insulin pharmacokinetics.
Factor Eﬀect on insulin pharmacokinetics
Physical status
(i) Soluble insulin
(ii) Insulin suspensions
(iii) Biphasic insulin
mixtures
Although insulin glargine molecule is soluble in formulation, the reduced solubility at neutral pH results in the
formation of microprecipitates upon SC injection with delayed absorption as a result [84]. Adding protamine to
the insulin formulation results in formation of insulin crystals in the formulation which are injected into the SC
tissue, thus prolonging the pharmacokinetic proﬁle of NPH insulin (insulin suspension) [34, 79]. Suspensions and
biphasic insulin mixtures are often associated with a larger pharmacokinetic variability between injection
compared to insulin preparations in homogenous solution [10, 18, 80–82, 111]
Concentration
There exists an inverse relationship between insulin concentration and the insulin absorption of soluble insulin
from the SC tissue, reﬂected by a delayed absorption with increasing insulin concentration [34, 64, 98, 99]. The
eﬀect of concentration on insulin pharmacokinetics does not apply to all soluble insulin preparations, for example,
the 200U insulin degludec and insulin lispro [103, 104]. The pharmacokinetics of insulin suspensions is also
aﬀected by insulin concentration. For NPH insulin, the concentration of insulin crystals increases with insulin
concentration with delayed SC absorption as a result [34]. Finally, for soluble insulin that precipitates in SC tissue,
that is, the 300U insulin glargine formulation, increasing the concentrations will result in decreased depot surface
area from which dissolution and absorption can occur resulting in delayed absorption from the SC tissue [37, 102]
Injection volume
Soluble insulin that does not precipitate in the SC tissue will diﬀuse and increase in volume upon SC
injection, resulting in depot dilution. The relative increase in depot volume and consequently depot dilution
occurs faster for small- compared to large-volume depots [34]. Smaller depots will also have a relatively
larger surface-to-volume ratio that increases the diﬀusion area of the injection depot [101]. The result is a
relatively faster absorption with smaller injection volumes [34, 98, 107]
Size
Decreased molecular size, such as the formation of insulin monomers, increases the rate of absorption [66]
while increases in size of the insulin molecule by means of PEGylation [87, 90] or the self-association of insulin
molecules into larger structures such as di- or multihexamers [20, 33] delay insulin absorption from the SC tissue.
Furthermore, the large insulin molecules achieved by PEGylation or albumin binding of insulin reduces the
insulin clearance rate and subsequently prolongs the half-life in the circulation [20, 40, 87, 89–91]
Excipients
The pharmacokinetic proﬁle of insulin can be modiﬁed by excipients added to the formulation. Excipients such
as niacinamide [112], BioChaperone [76], hyaluronidase [77, 78], citrate, and treprostinil [72–74] enhance
the absorption rate of insulin by a variety of mechanisms, including eﬀects on association state of insulin,
subcutaneous blood ﬂow, vascular permeability, insulin diﬀusion, or depot distribution in the SC tissue, while
protamine, zinc, and phenol [32, 34] can also inﬂuence the absorption of certain insulin molecules by altering
the association state of insulin
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deltoid and thigh region in healthy subjects in a study by
Braak et al. [125]. The diﬀerence was most evident with
human insulin where the time to maximum plasma insulin
concentration (Tmax) using abdominal injections was less
than half of those achieved with the two other injection sites.
Cmax was also signiﬁcantly lower upon injection into the
thigh and deltoid compared to abdominal injection (reﬂected
by a 32% and 42% reduction, resp.). The total insulin
exposure (area under the curve; AUC0–∞), however, did
not diﬀer signiﬁcantly between the injection sites. Also in
people with diabetes, Cmax has been reported to be 28%
higher and occur more than twice as fast upon injection
of human insulin into the abdomen compared to the thigh
[122]. Moreover, diﬀerent insulin absorption rates within
the same region have also been reported in people with
type 1 diabetes. Here, the insulin absorption was observed
to occur faster after abdominal injection above compared to
injections made below or lateral to the umbilicus [124].
Hence, random rotation between and within injection
regions should be avoided since it likely represents a
signiﬁcant source of pharmacokinetic variability between
injections [124, 131].
Knowledge about regional diﬀerences in insulin absorp-
tion rates helps clinicians and people with diabetes adjust
insulin therapy according to speciﬁc conditions. Since a
faster absorption from the abdomen results in a higher and
faster onset of Cmax compared to insulin injected into the
thigh and vice versa [67, 122, 125, 132], the abdominal region
is often the preferred site for the administration of prandial
insulin as it more eﬀectively reduces postprandial hypergly-
caemia compared to, for example, the thigh [130]. In
addition, it also allows for more ﬂexible administration
according to meal times. In contrast, when administrating
basal insulin, it is advisable to inject into the thigh region
or buttocks in order to prolong the absorption rate and
reduce the injection frequency. However, the sensitivity to
injection regions may not be universal. The absorption
of, for example, insulin glargine and insulin degludec,
has been reported not to be signiﬁcantly inﬂuenced by
injection region in healthy subjects, which can likely be
explained by the steady state achieved with the use of
these long-acting insulin preparations, as this renders their
pharmacokinetic proﬁle less susceptible to changes in
absorption rate [84, 133].
Table 3: Factors related to the injection site/patient that inﬂuence insulin pharmacokinetics.
Factor Eﬀect on insulin pharmacokinetics
Subcutaneous blood ﬂow (SBF)
at injection site
Increased SBF accelerates insulin absorption [113, 114]. SBF is inﬂuenced by several factors.
Increasing temperatures [113] and exercise [128] increase SBF, whereas obesity [114, 127, 135, 136]
and smoking [119] decrease SBF. SBF is also increased in the abdomen and arm/deltoid compared
to the thigh and buttocks [114] and during a supine compared to sitting position [121]
Lipohypertrophy
Lipohypertrophy delays absorption, and injection into these areas increases
within-subject pharmacokinetic and pharmacodynamic variability between
injections [137–140] and should be avoided [141]
Skin temperature Increasing skin temperatures accelerate insulin absorption [99, 113, 115, 117, 120]
Local degradation
Aﬀects the bioavailability of insulin, which is lower for insulin suspensions and biphasic insulin
mixtures compared to soluble insulin [111, 142–148]
Local massage
Massage of the injection site accelerates insulin absorption [115, 116, 134], likely due to an increased
insulin depot surface-to-volume ratio and not increased SBF [134]
Injection site
(i) Abdomen, arm/deltoid,
thigh, or buttocks
Insulin is more readily absorbed from the abdomen and deltoid region compared to thigh and
buttocks [111, 115, 118, 122–125, 130]. The pharmacokinetic proﬁle of long-acting insulin
preparations has been reported to be less susceptible to changes in absorption rate associated
with injection site rotation [84, 133].
Administration route
(i) Subcutaneous versus
intramuscular
Insulin is absorbed faster after intramuscular compared to SC injections [126, 149]. Intramuscular
injections should be avoided as they increase the risk of hypoglycaemia [141] but may be taken
into use under certain rare circumstances (e.g., in case of ketoacidosis or dehydration) [86]
Blood glucose levels
Hypoglycaemia has been reported to have no inﬂuence [150, 151] or decrease [152]
the absorption of insulin in healthy [151, 152] and diabetic subjects [150].
Diabetes related comorbidities
and complications
For example, oedema has been reported to delay SC absorption [153]
Obesity
Obesity gives rise to a decreased insulin absorption rate [99, 114, 129, 135]. High variation in
skinfold thickness between patients may contribute to the high pharmacokinetic variability
between people with diabetes [135]
Exercise and activity level
Exercise accelerates insulin absorption [118, 126], and therefore, the insulin dose should be
adjusted accordingly to reduce the risk of iatrogenic hypoglycaemia [154]
Smoking Causes peripheral vasoconstriction and delays insulin absorption [119]
Body position
Compared to a supine position, a sitting position is associated with reduced
SBF and delayed insulin absorption [121]
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Exercise and increasing skin temperatures both inﬂuence
insulin absorption [99, 117, 118, 120, 126]. Heating the
injection site to 40°C prior to and 60 minutes after admin-
istration of insulin aspart has been reported to reduce
Tmax by 42% in persons with type 1 diabetes [120].
Similarly, exercise increases the absorption rate [118, 126].
In addition, the regional diﬀerences in insulin absorption rate
are likely maintained during exercise, that is, insulin is still
absorbed faster from the abdominal region compared to the
thigh as reported for human insulin [118]. When taking the
eﬀect of temperature and exercise into account, it is advisable
to reduce the insulin dose and perhaps inject into the slower-
absorbing regions under these conditions in order to reduce
the risk of iatrogenic hypoglycaemia. In contrast, in order
to achieve a rapid decrease in blood glucose levels, for
example, in case of high postprandial hyperglycaemia, some
reports suggest to inject into the abdomen and massage or
heat the injection site in order to achieve the most rapid
glycaemic response [116, 120, 134].
4.2.1. SC versus Intramuscular Injections. For purely SC
administrations, the depth of the injection does not seem
to be of major importance for the insulin absorption rate
[124]. Due to increased blood ﬂow, the intramuscular
administration route is associated with a more rapid insu-
lin absorption [111, 126]. In people with type 1 diabetes,
the time until 50% of the insulin has been absorbed
(T50%) occurs twice as fast after intramuscular compared
to SC injections into the thigh, and this diﬀerence is even
more evident during light physical activity [126]. Acciden-
tal intramuscular injection may thus represent a major
source of pharmacokinetic variability between injections,
especially in lean people with type 1 diabetes [9, 141, 155].
Intramuscular administration should therefore be avoided
but may be taken into use under certain circumstances
(e.g., in case of ketoacidosis or dehydration) [86, 141].
4.2.2. Obesity. Obesity has been reported to be associated
with delayed insulin absorption [99, 114, 129, 135]. This
may in part be attributed to decreased SBF as a result of
an overall decrease in capillary density in the SC tissue
[114, 127, 135, 136, 156]. Increased skinfold thickness
has also been associated with increased steady-state insulin
depot size in persons with diabetes during continuous
subcutaneous insulin infusion (CSII) [157], likely as a
result of delayed absorption. The considerable diﬀerence in
skinfold thickness may partly explain the large between-
subject variability in insulin depot size, SBF, and insulin
absorption among people with diabetes [135, 157]. Despite
the delayed absorption, the regional diﬀerences in insulin
absorption rate appear to be maintained with obesity [114].
Dermal and SC thickness in the abdomen and thigh has
been reported to be inﬂuenced by BMI, gender, and age in
children and adults with diabetes in a study by Derraik
et al. [158]. In this study, there was an age-dependent
increase in dermal and SC thickness in children. In adults,
however, aging was in contrast associated with decreased
dermal and SC thickness. As expected, dermal and SC tissue
thickness increased with BMI in both children and adults.
Furthermore, men had an increased dermal thickness com-
pared to women whereas women had a 19% and 80% thicker
SC layer in the abdomen and thigh, respectively [158].
Similar diﬀerences in SC thickness between genders have also
been reported in a study including healthy subjects where
women exhibited a 30% and 95% increase in SC thickness
in the abdomen and thigh, respectively, compared to men
[159]. In addition to gender-related diﬀerences in anthro-
pometry, the thickness of the SC tissue also varies within
subjects from one region to another, for example, reﬂected
by increased thickness in the abdominal region compared
to the thigh [158]. Thus, diﬀerences in dermal and SC thick-
ness represent sources of variation if not appropriately taken
into account. The abovementioned observations underline
the importance of choosing the appropriate needle size when
administrating insulin. However, in both children and adults,
even the shortest needles (4mm) reliably transverse the skin
[141]. Use of the shortest needles available is therefore
recommended (the 4mm pen and 6mm syringe needle) as
their use minimize the risk of intramuscular injection which
occurs more frequently with longer needles, in slim and
young patients, males, and those who use limbs rather than
truncal sites for insulin injection [141] (Table 4). The impor-
tance of a correct injection technique will be discussed next.
4.3. Injection Technique. A proper injection technique is a
prerequisite in achieving optimal glycaemic control. Thera-
peutic education of health care professionals and people with
diabetes according to certain guidelines is therefore of
uttermost importance. The international recommendations
on insulin delivery provide such a guide, and the recommen-
dations are scored according to the strength and the degree of
scientiﬁc support [141]. Some of the factors related to the
injection technique that can inﬂuence insulin pharmacoki-
netics are listed in Table 4 along with the recommendations
on how to reduce the impact of these factors on the pharma-
cokinetic variability between injections. These factors include
the importance of choosing the appropriate needle size in
order to reduce the risk of intramuscular injection, how to
adequately mix insulin suspensions before use, and how to
avoid leakage of insulin associated with pen withdrawal or
injection of larger volumes. The guidelines also provide
recommendations on how to avoid lipodystrophy—a fat
tissue disorder that will be reviewed more in detail later—by
correct injection site rotation within injection regions and
avoiding reuse of needles. Strategies for reducing pain and
anxiety in persons with diabetes and recommendations on
use of continuous SC insulin infusion are also included.
Finally, some of the areas that should be addressed fur-
ther in order for the guidelines to be improved are also
highlighted. These include injections during pregnancy,
injections using the newer analogues or GLP-1 receptor
agonists, and injections in special populations (e.g., babies
and the very elderly) or under special conditions (e.g., SC
oedema). For more information on injection technique and
insulin delivery, please refer to the guidelines on insulin
delivery recommendations [141].
Use of jet injection, where insulin is administered at
high velocity across the skin, instead of conventional pen
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administration has been shown to accelerate absorption of
insulin aspart in healthy subjects and persons with diabe-
tes [162, 163]. The jet injection results in the depot being
dispersed in a spray-like manner in the SC tissue, thus
increasing the surface-to-volume ratio of the injection
depot that is likely the mechanism behind the accelerated
absorption [163]. Elsemiek et al. observed a 40% shorter
Tmax and a signiﬁcantly higher Cmax with jet compared
to pen administration in healthy subjects [162]. Moreover,
use of jet injection has also been reported to be beneﬁcial
in terms of diminishing the obesity-associated delay in
insulin absorption compared to pen injections [129, 164].
So far, the use of jet injectors in the diabetic community
is limited. In addition to greater expenses, the use of jet
injection devices requires proper training since inaccurate
use increases the risk of incorrect dosing and mild skin
trauma such as bleeding and bruising [164, 165].
4.4. Local Degradation at the Injection Site. Little is known
about the fate of the insulin that does not reach the systemic
circulation after injection into the SC tissue. Insulin degrada-
tion presumably takes place at the injection site, but the
reported extent of degradation varies considerably between
the few, mostly older studies that have been conducted so
far [18, 111, 142–148]. Nevertheless, insulin bioavailability
varies for diﬀerent types of insulin preparations indicating
that some degradation occurs in the SC tissue. Insulin
bioavailability has, for example, been estimated to be
similar for human insulin and analogues in rapid-acting
insulin preparations, whereas it is lowest for insulin sus-
pensions and biphasic insulin mixtures, decreasing with
the crystal-to-soluble ratio and with increasing concentra-
tions [18, 125]. This may partly be explained by activation
of the local immune response by insulin crystals: whereas
degradation of soluble insulin preparations is assumed to
occur enzymatically, invading macrophages are believed to
play a major role in the degradation of insulin crystals [18].
Consequently, besides aﬀecting insulin absorption in general,
SBF also inﬂuences bioavailability of crystalline insulin, specif-
ically. This is probably due to a high sensitivity of crystalline
insulin to blood ﬂow changes, since higher SBF increases the
dissolution of crystals and consequently decreases the time
available for macrophage degradation [18].
Blood-derived proteases may to some degree be present
in the SC tissue [17]. However, cells of the ECM can also
secrete proteases, and the secretion may be stimulated by a
local inﬂammation induced by needle penetration. Fibro-
blasts are most likely the source of these proteases, and their
activity is regulated by a variety of cytokines [21]. Accord-
ingly, administrations of protease inhibitors have been
associated with increased insulin bioavailability [166].
Addition of the protease inhibitor aprotinin to the insulin
formulation has been shown to accelerate absorption of
human insulin in healthy subjects, reﬂected by 27% increase
and earlier onset of Cmax. However, these results may also
partly be the result of a local increase in SBF induced by apro-
tinin [167]. Nevertheless, due to the risk of adverse eﬀects
and insuﬃcient data, the use of protease inhibitors in combi-
nation with insulin has so far not been approved [166].
4.5. Lipodystrophy. Repeated injections of insulin into the
same skin area can induce lipodystrophic changes in the SC
Table 4: Factors related to the injection technique that inﬂuence insulin pharmacokinetics and international recommendations on insulin
delivery that aim at reducing pharmacokinetic variability between injections.
Factor Eﬀect on insulin pharmacokinetics International recommendations on insulin delivery [141]
Needle size
Age and gender, for example, have signiﬁcant
inﬂuence on the anthropometry in people
with diabetes and should therefore be taken into
account when choosing needle length and dosing
strategy [158] in order to reduce the risk of
intramuscular injection
Use of the shortest needles is recommended (the 4mm
pen and 6mm syringe needle). In order to decrease the
risk of intramuscular injections, the 4mm needle should
be used for injection in children and young adults. Lifting
of a skinfold prior to injection or injection at a 45° angle
may further reduce the risk of intramuscular injection
Time before withdrawal
Rapid withdrawal may result in loss of insulin and
increased pharmacokinetic variability between
injections [141]
With use of insulin pens, patients should count to
10 after the plunger is fully depressed before
removing the needle from the skin
Dispersion
Dispersion of the injection volume gives rise to a
more rapid absorption [108]
Larger doses may be split to reduce the volume
of insulin and avoid leakage
Mixing
Inadequate resuspension is a problem with
insulin suspensions (e.g., NPH insulin) and
contributes to pharmacokinetic variability
between injections [82, 141]
It is recommended to gently roll and tip cloudy
insulin until the crystals are resuspended
(the solution becomes milk white)
Needle reuse
Reuse of needles increases the risk of
lipodystrophy [160, 161]
Reusing insulin needles is not an optimal
injection practice, and patients should be
discouraged from doing so
Rotation
Rotation between injection sites reduces the
prevalence of lipodystrophy [141, 160, 161], but for a
number of insulin preparations, rotation also elicits
diﬀerent pharmacokinetic and pharmacodynamic
responses [111, 115, 118, 122–125, 130]
Patients should be encouraged to avoid injecting
into areas of lipohypertrophy, and injections should be
rotated by injecting at least 1 cm from previous injection
(i.e., within the same injection region)
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tissue [160, 161]. Lipodystrophy comprises both lipoatrophy
and lipohypertrophy, and its prevalence is highest in children
and young patients with type 1 diabetes [168, 169]. Lipoatro-
phy is believed to be caused by immunological factors,
and—as with insulin antibodies—its prevalence has been
signiﬁcantly reduced since the availability of more puriﬁed
insulin preparations and the introduction of recombinant
human insulin and insulin analogues [169]. Hence, we
will only review the clinical impact of lipohypertrophy in
this section.
Lipohypertrophy is believed to be a nonimmunological
side eﬀect caused by the anabolic potential of insulin, occur-
ring irrespective of administration route [7, 169, 170]. In a
recent study, the prevalence of lipohypertrophy was reported
to be as high as 76% and 56% in people with type 1 and type 2
diabetes, respectively [160]. Although lipohypertrophy is not
believed to be caused by immunological factors, insulin
antibody titres have been reported to correlate with the
degree of lipoatrophy and lipohypertrophy in young people
with type 1 diabetes [171]. However, a direct role of insulin
antibodies in the pathogenesis of lipohypertrophy has still
not been established [170].
Compared to normal SC tissue, the SC tissue in
lipohypertrophied areas is more ﬁbrous and has a poorer
blood supply. Consequently, lipohypertrophy is associated
with delayed insulin absorption, reduced bioavailability
(potentially due to a higher degree of local degradation),
and increased pharmacokinetic variability between injections
[137, 138, 168]. One study conducted in people with type 1
diabetes showed that compared to injection of insulin aspart
into normal abdominal tissue, injection into lipohypertro-
phied tissue resulted in a 25% and 22% decrease in insulin
Cmax and 4-hour insulin exposure (AUC0–4h), respectively
[138]. Similar results have been reported for NPH injected
into the thigh region and human insulin injected into
abdomen, thigh, or deltoid [139, 140]. Repeated injection of
insulin lispro into lipohypertrophic areas has been reported
to result in increased variability between injections in certain
pharmacokinetic and pharmacodynamic parameters in
patients with type 1 diabetes [137]. Here, the coeﬃcients of
variation (CVs) for AUC0–4h and Cmax were as high as 52%
and 55% upon injection into lipohypertrophic areas
compared to 11% and 15% upon injection into normal SC
tissue. Consequently, the variability in 4 h glucose exposure
(AUCGIR0–4h) was also higher with injection into lipohyper-
trophic areas reﬂected by CVs of 57% compared to 23% in
normal tissue. Others have also reported lipohypertrophy to
be associated with higher prevalence of hypoglycaemia and
increased glucose variability (blood glucose readings above
or below 13.9 and 3.3mM, respectively, at least three times
a week) [160]. Thus, besides being perceived as an aesthetical
problem, lipohypertrophy can increase pharmacokinetic
variability between injections if patients repeatedly inject into
these areas or rotate between lipodystrophy-aﬀected and
unaﬀected injection sites.
Reported risk factors for development of lipodystrophy
include BMI, injection technique, number of injections per
day, duration of treatment, size of the area usually used for
injection, and frequency of changing injection sites and
needles [160, 161, 169]. Unfortunately, many patients prefer
to inject insulin into lipodystrophic tissue, since pain sensa-
tion is lower in these areas, although it worsens the condition
[169]. While rotation of injection sites is highly preventive in
the development of lipodystrophy [160, 161, 168], this proce-
dure will increase the pharmacokinetic variability between
injections, as mentioned earlier [131]. A compromise is
therefore recommended consisting of systematic rotation
within one region in order to both prevent development of
lipodystrophy while simultaneously reducing the pharmaco-
kinetic variability associated with random injection into
diﬀerent regions [86, 141] (Table 4). Consequently, although
reducing the intraregional variability in insulin absorption
due to a reduced number of injections, the use of insulin
pumps may increase the incidence of lipodystrophy due to
reduced capacity to rotate injection sites [170].
4.6. Other Factors. People with diabetes are at increased risk
of developing secondary comorbidities and complications.
This can alter the pharmacokinetic proﬁle of insulin, for
example, insulin absorption in patients with severe oedema,
which may signiﬁcantly delay insulin absorption [153]. In
addition, factors such as age, gender, and anthropometry
may inﬂuence insulin pharmacokinetics due to diﬀerences
in volume of distribution, insulin degradation, and clearance
between patients. However, the abovementioned factors
likely only give rise to between-subject variability and thus
insulin doses and injection strategies can be adjusted accord-
ing to these factors in people requiring insulin therapy.
5. Discussion and Future Perspectives
Many studies that have assessed variability in insulin
absorption and action so far have focused on variability
between injections associated with use of diﬀerent insulin
preparations [80, 81, 96, 97, 103, 111, 137, 172–179]. Even
under strictly controlled conditions, identical doses of all
insulin preparations to some degree elicit diﬀerent pharma-
cokinetic and pharmacodynamic responses between injec-
tions in the same patient. Several studies have investigated
how physiological factors aﬀect the absorption of insulin that
naturally gives rise to pharmacokinetic variability if not taken
into account; that is, if patients randomly rotate between
injection sites, diﬀerent absorption rates and metabolic
eﬀects may be observed from one injection site to the next.
However, not many studies have assessed within-subject
pharmacokinetic variability associated with, for example,
repeated SC injection into tissue from obese subjects, dehy-
drated versus hydrated tissue, diﬀerent injection regions,
and tissue from patients with comorbidities, to quantify the
variability associated with these variables per se. Information
from such studies could help clinicians and people with
diabetes adjust regimens and dosing strategies according to
these factors in order to achieve the best glycaemic result.
Moreover, an area that has received even less attention in
terms of assessing variability in insulin absorption is the SC
microenvironment. Thus, there is a need to characterize what
factors inﬂuence both distribution and kinetics of the
injection depot in the SC tissue in vivo. These factors could
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be related to diﬀerences in the composition of interstitial
ﬂuid (e.g., ionic content, pH, and charge), the architecture
of the SC tissue (e.g., collagen and elastin content), and/or
proteins and cell types/density present—and these compo-
nents may well vary between regions and within region over
time. Furthermore, there is a need to investigate how diﬀer-
ent disease states (e.g., obesity, hypertension, and oedema)
aﬀect the SC microenvironment. This information is both
of clinical relevance and may also lead to new insulin
analogue candidates that may be more resistant to changes
in the SC environment at the site of injection.
As previously mentioned, insulin therapy should ideally
mimic the physiological release of endogenous insulin. Any
imbalance between the insulin concentration proﬁle and
physiological insulin demands thus represents a source of
glucose variability in people using SC insulin therapy.
Consequently, reducing the glucose variability associated
with SC injections of insulin also goes beyond achieving
reproducible pharmacokinetic proﬁles, making establish-
ment of glycaemic control in people with diabetes even
more challenging. In addition to adjusting the insulin dose
under certain circumstances as discussed previously (e.g.,
during exercise), insulin delivery systems that deliver insu-
lin according to metabolic needs, that is, insulin pumps
combined with glucose sensors that adjust the insulin dose
according to blood glucose levels, likely represent an impor-
tant future step in reducing glucose variability in people
using SC insulin therapy.
6. Conclusion
Currently, all people with type 1 diabetes and many with
type 2 diabetes require insulin therapy in order to achieve
glycaemic control. However, variability in insulin absorp-
tion represents an important source of glucose variability
in these subjects.
When assessing variability associated with the absorption
of insulin, several factors need to be considered. These factors
relate to the insulin preparation, the injection technique, and
the individual. Education and correct instruction of clini-
cians and patients according to available information about
such factors are essential in order to achieve the best glycae-
mic result, improve the long-term prognosis, and increase
quality of life in people with diabetes that use insulin.
However, information regarding factors driving this
variability is lacking—in particular factors related to the
patient and the injection site. Thus, further studies assessing
endogenous factors and their contribution to the insulin
absorption process are necessary in order to further improve
insulin therapy.
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